Professional Documents
Culture Documents
E2 Non Surgical Acute Abdomen
E2 Non Surgical Acute Abdomen
Physician Associate
Overview of the acute abdomen presentation
and the pitfalls of diagnosis
Overview of region related abdominal
pathology
Revisiting the RED FLAGS
A look at the potential medical causes
3 interactive case studies
Questions
Term ‘ Acute abdomen‘ represents rapid onset of severe abdominal
symptoms
Formulae:
Anion gap = (Na⁺ + K ⁺ ) – (HCO3⁻ + Cl ⁻)
(133+4) - (18+93)
Answer = ?
26
Infarction
Insufficient Insulin
In meantime
Give MONA if not given
Beta Blocker and ACE (under specialist guidance)
Cannula left hand
Cardiac Monitor
18 year old female presented to A/E with 5 day history of
severe abdominal pain.
Located in epigastric and umbilical region
Intermittent and severe in nature
Associated with nausea and vomiting (not hematemesis)
Denied dysurea, increased urinary frequency, chills ,fevers
or change in bowel habit.
She was not sexually active and it was the first day of
menstruation.
Periods tended to be irregular
She had had previous admissions for severe abdominal
pain associated with menstruation and a mild
hyponatraemia was noted.
No cause had been found.
PMH depression, previous incidents of
pharmacological and physical DSH.
Medication
Citalopram, tetracycline (for acne)
Observations temp 37.5, HR 110, BP 138/77, RR 20,
Sats 97% air.
Abdominal examination showed reduced bowel
sounds, tenderness on deep palpation in
periumbilical region.
Pelvic exam revealed a normal cervix and no adnexal
tenderness
PR normal no blood
Neurological Examination
Showed hypo-reflexia
What is your differential diagnosis?
This reaction is considered the rate-limiting step in heme biosynthesis and is subject to
feedback regulation by heme, the end product of the pathway.
AIP results from partial deficiency of PBG deaminase, leading to accumulation and
excess urinary excretion of toxic porphobilinogen and ALA.
High doses of glucose (400 g/d) can inhibit heme synthesis and are
useful for treatment of mild attack by reducing the production of
toxic porphyrin precursers (ALA and porphobilogen).